Literature DB >> 35089586

Coronavirus enzyme inhibitors-experimentally proven natural compounds from plants.

Junsoo Park1, Rackhyun Park2, Minsu Jang2, Yea-In Park2, Yeonjeong Park2.   

Abstract

Coronavirus disease (COVID-19) can cause critical conditions that require efficient therapeutics. Several medicines are derived from plants, and researchers are seeking natural compounds to ameliorate the symptoms of COVID-19. Viral enzymes are popular targets of antiviral medicines; the genome of coronaviruses encodes several enzymes, including RNA-dependent RNA polymerase and viral proteases. Various screening systems have been developed to identify potential inhibitors. In this review, we describe the natural compounds that have been shown to exert inhibitory effects on coronavirus enzymes. Although computer-aided molecular structural studies have predicted several antiviral compound candidates, the current review focuses on experimentally proven natural compounds.
© 2022. The Microbiological Society of Korea.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; coronavirus; natural compounds

Mesh:

Substances:

Year:  2022        PMID: 35089586      PMCID: PMC8795716          DOI: 10.1007/s12275-022-1499-z

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   2.902


  78 in total

1.  Natural product drug discovery and development: the United States National Cancer Institute role.

Authors:  Gordon M Cragg
Journal:  P R Health Sci J       Date:  2002-06       Impact factor: 0.705

2.  Tannic acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease.

Authors:  Shao-Chun Wang; Yeh Chen; Yu-Chuan Wang; Wei-Jan Wang; Chia-Shin Yang; Chia-Ling Tsai; Mei-Hui Hou; Hsiao-Fan Chen; Yi-Chun Shen; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

3.  Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute respiratory syndrome coronavirus.

Authors:  Ji-Young Park; Hyung Jae Jeong; Jang Hoon Kim; Young Min Kim; Su-Jin Park; Doman Kim; Ki Hun Park; Woo Song Lee; Young Bae Ryu
Journal:  Biol Pharm Bull       Date:  2012-09-03       Impact factor: 2.233

4.  Bioactive constituents and medicinal importance of genus Alnus.

Authors:  Sushil Chandra Sati; Nitin Sati; O P Sati
Journal:  Pharmacogn Rev       Date:  2011-07

5.  Combating devastating COVID-19 by drug repurposing.

Authors:  Ashish Yashwantrao Pawar
Journal:  Int J Antimicrob Agents       Date:  2020-04-17       Impact factor: 5.283

6.  Epigallocatechin Gallate Inhibits the Uridylate-Specific Endoribonuclease Nsp15 and Efficiently Neutralizes the SARS-CoV-2 Strain.

Authors:  Seokho Hong; Sang Hwan Seo; Sun-Je Woo; Yonghoon Kwon; Manki Song; Nam-Chul Ha
Journal:  J Agric Food Chem       Date:  2021-05-21       Impact factor: 5.279

7.  Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease.

Authors:  Yunjeong Kim; Sivakoteswara Rao Mandadapu; William C Groutas; Kyeong-Ok Chang
Journal:  Antiviral Res       Date:  2012-11-28       Impact factor: 5.970

8.  Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2.

Authors:  Youngchang Kim; Robert Jedrzejczak; Natalia I Maltseva; Mateusz Wilamowski; Michael Endres; Adam Godzik; Karolina Michalska; Andrzej Joachimiak
Journal:  Protein Sci       Date:  2020-05-02       Impact factor: 6.993

9.  Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro.

Authors:  Seri Jo; Suwon Kim; Dae Yong Kim; Mi-Sun Kim; Dong Hae Shin
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

Review 10.  Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.

Authors:  Prashant Khare; Utkarsha Sahu; Satish Chandra Pandey; Mukesh Samant
Journal:  Virus Res       Date:  2020-09-24       Impact factor: 3.303

View more
  1 in total

1.  Two years of COVID-19 pandemic: where are we now?

Authors:  Jinjong Myoung
Journal:  J Microbiol       Date:  2022-03       Impact factor: 3.422

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.